Biocon Biologics Receives Japan Approval for Pegfilgrastim Biosimilar
MM Desk
26 August, 2026
Biocon Biologics Ltd, a wholly owned subsidiary of Biocon Ltd, has received marketing approval from
Biocon Biologics Ltd, a wholly owned subsidiary of Biocon Ltd, has received marketing approval from
Biocon Biologics Limited, a global biosimilars company and a subsidiary of Biocon Limited (BSE: 532523,
Biocon Biologics Ltd (BBL), a global, fully integrated biosimilars company and a subsidiary of Biocon
Biocon Biologics Limited, a fully integrated global biosimilars company and a subsidiary of Biocon Limited,
Biocon Biologics Limited, a fully integrated global biosimilars company and a subsidiary of Biocon Limited,
Biocon Biologics Ltd (BBL), a wholly owned subsidiary of Biocon Ltd (BSE: 532523, NSE: BIOCON),
Centum S&P Global Ratings has revised its outlook on Biocon Biologics Limited, moving the company
Biocon Limited (BSE: 532523, NSE: BIOCON), a global biopharmaceutical innovator, has announced plans to fully
Biocon Biologics Ltd (BBL), a global biosimilars manufacturer and subsidiary of Biocon Ltd., has reached
Biocon Biologics Ltd (BBL), a global biopharmaceutical company and subsidiary of Biocon Ltd has received